Bridgepoint takes majority stake in HTL Biotechnology
Context
Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior. In this new capital structure, Naxicap Partners retains a significant minority interest, signaling continued confidence in the company's growth trajectory and industrial potential. The rationale for the transaction is rooted in HTL,s exceptional profitability and its unique position in a high-barrier-to-entry niche of the biotechnology sector. With Bridgepoint,s support, HTL aims to accelerate its international transformation, moving beyond its historical European stronghold to capture market share in North America and Asia.
The acquisition of HTL Biotechnology is part of the growth strategy of Bridgepoint, which already has several external growth operations under its belt, notably Zenith in 2017.
HTL Biotechnology, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.
-> Deep-dive in Healthcare & Pharma market trends
Target
Founded in the late 20th century, HTL is a leading global biotechnology company specializing in the development, production, and purification of pharmaceutical-grade hyaluronic acid and other bio-sourced polymers. Based in Brittany, the company utilizes advanced fermentation and purification processes to supply high-purity ingredients to the global healthcare industry. Its value proposition is centered on technical excellence and the ability to provide customized molecular weights for sensitive medical applications, including dermatology for wrinkle filling, ophthalmology for cataract surgery, and rheumatology for joint treatments. HTL,s strategy focuses on continuous innovation through significant R&D investments and the expansion of its industrial capacities to maintain a leadership position in the high-end biopolymer market. By maintaining a discreet but critical role in the pharmaceutical supply chain, the company ensures that global medical device and pharma manufacturers have access to safe, natural, and highly effective components for life-changing medical treatments.
Ent. Value
€500M–1.5bn
Equity Value
[members only]
Multiples
EV / Revenue
Above 6x
EV / EBITDA
15x–25x
EV / EBIT
[members only]
Historical Financials (EUR)
Other operations with HTL Biotechnology
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
Other operations with Bridgepoint
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2020 | BRIDGEPOINT | KEREIS | FRANCE | Brokerage |
| 01/2019 | BRIDGEPOINT | MIYA WATER | SPAIN | Water |
| 01/2017 | BRIDGEPOINT | ZENITH | UNITED KINGDOM | Fleet Management Finance |
| 12/2016 | BRIDGEPOINT | ROVENSA | PORTUGAL | Specialty Chemicals |
| 11/2016 | BRIDGEPOINT | VITAMIN WELL | SWEDEN | Soft Drinks |
| 06/2016 | BRIDGEPOINT / RAISE / FLEXSTONE PARTNERS | ACTEON | FRANCE | Medical Devices |
| 12/2015 | BRIDGEPOINT | ELEMENT MATERIALS TECHNOLOGY | UNITED KINGDOM | TIC (Testing, Inspection, Certification) |
| 01/2015 | BRIDGEPOINT | EFRONT | FRANCE | Financial Services / Banking |
| 12/2014 | BRIDGEPOINT | AZZURRI GROUP | UNITED KINGDOM | Restaurants / Chains |
| 05/2013 | BRIDGEPOINT | FLEXITALLIC GROUP | UNITED STATES | Components |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 12/2018 | MERCK & CO. | ANTELLIQ | FRANCE | Animal Health |
| 11/2018 | ARDIAN | NEOPHARMED GENTILI | ITALY | Generics / Labs |
| 10/2018 | ARDIAN | INULA GROUP | BELGIUM | Pharma & Biotech |
| 10/2018 | ASTORG | NEMERA | FRANCE | Medical Consumables |
| 10/2018 | GLANBIA | SLIMFAST | UNITED STATES | Nutrition & Dietary Supplements |
| 08/2018 | DENTRESSANGLE | ACTEON | FRANCE | Medical Devices |
| 05/2018 | PERMIRA | CORIN GROUP | UNITED KINGDOM | Implants & Prosthetics |
| 05/2018 | ZOETIS | ABAXIS | UNITED STATES | Diagnostic Equipment |
| 05/2018 | NN | PARAGON MEDICAL | UNITED STATES | Medical Devices |
| 12/2017 | PERKINELMER | EUROIMMUN MEDICAL LABORATORY DIAGNOSTICS | GERMANY | Diagnostic Equipment |
REFERENCES
Valuation range: EV €500M–1.5bn
Revenue range: €50–100M
EBITDA range: €25–50M
EV/Revenue range: Above 6x
EV/EBITDA range: 15x - 25x
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HTL Biotechnology by Bridgepoint are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Target: htl biotechnology
FAQ
What transaction does this page cover?
How was the acquisition of HTL Biotechnology by Bridgepoint valued, and what multiples were paid?
What were HTL Biotechnology’s revenue and EBITDA at the time of the deal?
What sources support the information on this transaction?
What is mynth?